Articles related to PSYCHEDELICS

In treatment-resistant depression, two studies found that COMP360 psilocybin therapy reduced depression and one study reported that using precision medicine for ketamine dosing might decrease the high efficacy-low effectiveness gap.

Incidences of dizziness, dissociation, increased blood pressure, nausea, vertigo, and sedation were highest in week 1 of treatment and the majority are mild or moderate in severity.

SI, sadness, and anxiety symptoms could all be effectively treated with ketamine. The high rates of response and remission in population samples of TRD were comparable to those for interventional therapies. Racemic ketamine infusion as the main treatment for SI requires randomized controlled trials and comparative efficacy studies with other therapies.

In this double-blind randomized clinical trial with 93 participants, the percentage of heavy drinking days during 32 weeks of follow-up was significantly lower in the psilocybin group than in the diphenhydramine group and was accompanied by a decrease in daily alcohol consumption.

In what is thought to be the largest study to date of any type of ketamine treatment, the findings revealed that, after four sessions, 89 percent of participants reported improvement in their depression and/or anxiety symptoms. On the PHQ-9 or GAD-7 scale, 63 percent of participants saw a 50% or greater improvement. PHQ-9 remission rates were 32.6 percent and GAD-7 remission rates were 31.3 percent. Furthermore, at the end of the four weeks, 62 percent of patients who had suicidal ideation prior to treatment reported no suicidal ideation.

Researchers studied the effects of four repeated low doses of LSD, administered under lab conditions every three to four days, using approximately 1/8th the dose typically used to “trip” on LSD.